Hot High Tech Stocks To Watch Right Now

Shutterstock

The US government balance sheet features $80 trillion to $200 trillion in unfunded liabilities. This amount stems from future entitlement program burdens that are, in effect, government promises.

No one is going to vote to reduce their entitlements. (Well, other than the very well-off, who dont actually need those entitlements.)

Unfunded pension liabilities at the state and local have swollen to roughly $4$6 trillion in the United States. And that may be understating the severity of the problem.

Kentucky Is an Example of How Severe This Problem Is

Its easy to cite Illinois or New Jersey, but lets look at a state like Kentucky.

The State of Kentucky released a remarkably candid self-appraisal of their pension liability issues earlier this year. If you optimistically (and unrealistically) assume between 6.75%7.5% compounded returns for the future, Kentucky still ends up $33 billion underfunded.

Hot High Tech Stocks To Watch Right Now: Chuy's Holdings, Inc.(CHUY)

Advisors’ Opinion:

  • [By Motley Fool Staff]

    Chuy’s Holdings (NASDAQ:CHUY) Q1 2018 Earnings Conference CallMay. 8, 2018 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Max Byerly]

    Chuy’s (NASDAQ:CHUY) CEO Steven J. Hislop sold 3,690 shares of the company’s stock in a transaction dated Friday, May 4th. The stock was sold at an average price of $30.00, for a total transaction of $110,700.00. Following the completion of the transaction, the chief executive officer now owns 132,460 shares in the company, valued at approximately $3,973,800. The sale was disclosed in a legal filing with the SEC, which is available through this link.

  • [By Joseph Griffin]

    Chuy’s (NASDAQ:CHUY) had its price target hoisted by BMO Capital Markets from $27.00 to $28.00 in a report published on Wednesday, Marketbeat.com reports. The firm currently has a hold rating on the restaurant operator’s stock.

Hot High Tech Stocks To Watch Right Now: Callaway Golf Company(ELY)

Advisors’ Opinion:

  • [By Shane Hupp]

    Callaway Golf (NYSE:ELY) insider Alex Mitchell Boezeman sold 47,012 shares of Callaway Golf stock in a transaction dated Friday, May 4th. The shares were sold at an average price of $17.19, for a total value of $808,136.28. Following the completion of the sale, the insider now owns 107,512 shares of the company’s stock, valued at $1,848,131.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

  • [By Joseph Griffin]

    Granite Springs Asset Management LLC increased its position in shares of Callaway Golf (NYSE:ELY) by 7.4% during the 1st quarter, Holdings Channel reports. The fund owned 72,500 shares of the company’s stock after buying an additional 5,000 shares during the quarter. Granite Springs Asset Management LLC’s holdings in Callaway Golf were worth $1,186,000 at the end of the most recent quarter.

Hot High Tech Stocks To Watch Right Now: Sanofi(SNY)

Advisors’ Opinion:

  • [By Cory Renauer]

    Amgen’s next-generation cholesterol drug, Repatha has finally started marching upwards in recent quarters, but it could stall out in the quarters ahead. One of America’s largest pharmacy benefits managers recently dropped Repathain favor of a rival therapy from Regeneron (NASDAQ:REGN) andSanofi (NYSE:SNY). That puts a lot of strain on the only other younger products generating significant sales growth right now.

  • [By Keith Speights]

    Alnylam’s partner, Sanofi (NYSE:SNY), is taking the lead on a phase 3 study of another experimental RNAi therapeutic,fitusiran, in treating hemophilia A and B. Sanofi now has global rights to the drug as a result of a restructuring of the two companies’ rare disease collaboration agreement signed in 2014. Alnylam stands to receive royalties between 15% and 30% of any future sales for fitusiran.

  • [By ]

    If thats not enough excitement for you, French drug maker Sanofi SA (NYSE:SNY) announced it’s buying Bioverativ (NASDAQ:BIVV) for $11.6 billion. The deal pushed BIVV shares up more than 60% by the closing bell.

  • [By Todd Campbell]

    One of these two drugs is Amgen’s (NASDAQ:AMGN) Repatha, and the other is Praluent, which was co-developed by Sanofi SA (NYSE:SNY) and Regeneron Pharmaceuticals (NASDAQ:REGN). Both drugs launched to billion-dollar blockbuster expectations, but because they’re complex biologics that are expensive to make, they cost about $14,000 per year. Their high cost, plus the fact that they’re injected rather than taken orally, may make them best suited for patients with stubbornly high cholesterol who are at the greatest risk of heart disease.

Hot High Tech Stocks To Watch Right Now: Celanese Corporation(CE)

Advisors’ Opinion:

  • [By Shane Hupp]

    Celanese (NYSE: CE) and Sealed Air (NYSE:SEE) are both basic materials companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

  • [By ]

    Eli Lilly announced in October it was conducting a strategic review for the unit.  Elanco on Monday said it has appointed Christopher Jensen, who was most recently with Celanese Corp. (CE) , as chief financial officer.

  • [By Ethan Ryder]

    Celanese (NYSE:CE)‘s stock had its “outperform” rating reiterated by Cowen in a report issued on Friday. They presently have a $125.00 price objective on the basic materials company’s stock, up from their previous price objective of $120.00. Cowen’s price objective would suggest a potential upside of 15.06% from the company’s previous close.